A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): survival of FIGO stage I-IIA patients

Jørn Herrstedt, J Huober, F Priou, HH Müller, M Baekelandt, C Kurzeder, J Pfisterer, A Stähle, I Ray-Coquard, A du Bois

Research output: Contribution to conference without publisher/journalConference abstract for conferenceResearch

Original languageEnglish
Publication date2009
Publication statusPublished - 2009
EventMeeting ASCO - Orlando, United States
Duration: 29. May 20092. Jun 2009
Conference number: 45


ConferenceMeeting ASCO
Country/TerritoryUnited States

Cite this